Asco 2025 · Posters · Cáncer de Mama · Bartomeu Fullana Grimalt, MD Volver

HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.

Abstract: 607
Poster Bd #: 200
Descargar Poster

Bartomeu Fullana Grimalt, MD

Instituto Catalán de Oncología

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo